SAVE MONEY ON TRAVEL DEALS

The trial was performed on 247 angina patients with native coronary artery lesions randomly assigned to receive 20 mg to 40mg/day of olmesartan or a placebo, and treated with a combination of beta-blockers, calcium channel blockers, diuretics, nitrates, glycemic control agents and/or statins per physician's guidance.

Examinations were performed to assess the amount of coronary plaque before and 14 months after the start of treatment.

At the start of the trial, patient characteristics and measurements were identical between the two groups. However, after 14 months of treatment, the measurement showed significant decreases in measurements of plaque volume in the olmesartan group, despite similar blood pressure readings.

"Management of plaque is a key front in the war on sudden heart attack", lead author Dr. Atsushi Hirohata of the Sakakibara Heart Institute of Okayama, Okayama, Japan, said in a statement. "These results suggest a positive role in potential plaque regression through the administration of olmesartan for patients with stable angina pectoris."

The finding were presented at the 20th annual Transcatheter Cardiovascular Therapeutics scientific symposium Washington.

 BREAKING STORIES

Pilot whales stranded on island

French soldier dies in Afghan mine sweep

Tibetan exiles support Dalai Lama policy

Labor group gives Thai government deadline

Arroyo's husband in Manila after illness

Indian forces blamed for Kashmir shootings

Fair advertises Afghan pomegranates

Search for bodies slow after collapse

Indian defends production of 'Dostana'

China to reduce income tax

Land prices drop in Japanese cities

Sexual harassment hurts job performance

Police say two dead in Shanghai blast

Bureaucrat stabbings possibly related

China to build pipeline through Myanmar

BNP to take part in Bangladesh polls

Sri Lanka claims major victory

Pakistan to protest latest U.S. strike

Garlic compound a potential diabetes drug

Vietnam's fourth largest oilfield opens